Volume 33, Issue 1 (April 2022)                   Studies in Medical Sciences 2022, 33(1): 37-44 | Back to browse issues page

Research code: 2454
Ethics code: IR.UMA.REC.1400.006

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

URL: http://umj.umsu.ac.ir/article-1-5704-en.html
Assistant Professor, Department of Microbiology, Faculty of Science, Mohaghegh Ardabili University, Ardabil, Iran (Corresponding Author) , nourizade@yahoo.com
Abstract:   (1112 Views)
Background & Aims: Despite the recognition of the parasite responsible for leishmaniasis in the world, unfortunately this disease is still considered as an endemic disease in many countries of the world and is spreading even with the predictions made. This trend is also observed in Iran. Considering this importance, the aim of this study is to investigate the effect of monoclonal antibodies in the diagnosis of Kalaazar disease, which is the visceral type of leishmaniasis.
Materials & Methods: Leishmania infantum promastigote forms were prepared in a special culture medium and then BALB/c mice were immunized with these forms. The mouse with the best response was selected and its spleen cells were merged with myeloma SP2/o cells. After the formation of hybridoma cells, specific antibody-producing cells were prepared as single clones.
Results: In this study, five clones 3E6 FIII3, 3E6 FIII4, 2C4 FII5, 2C4 FII3, and 2C4 FII2 were obtained. Among them, 3E6 FIII4, 2C4 FII5 and 2C4 FII2 monoclones which had the highest ODs were selected for investigation.
Discussion: Although these antibodies are not able to distinguish between different species of Leishmania parasite, but it seems that they can be used to further investigate Leishmania parasite antigens and also to diagnose Leishmaniasis.
Full-Text [PDF 451 kb]   (422 Downloads)    
Type of Study: Research | Subject: میکروبیولوژی

1. Stahlman S, Williams VF, Taubman SB. Incident diagnoses of leishmaniasis, active and reserve components, U.S. Armed Forces, 2001-2016. MSMR 2017;24(2):2-7. [Google Scholar]
2. Mody RM, Lakhal-Naouar I, Sherwood JE, Koles NL, Shaw D, Bigley DP, et al. Asymptomatic Visceral Leishmania infantum Infection in US Soldiers Deployed to Iraq. Clinical Infectious Diseases 2019;68(12):2036-44. [DOI:10.1093/cid/ciy811] [PMID] [PMCID]
3. Assefa A. Leishmaniasis in Ethiopia: A systematic review and meta-analysis of prevalence in animals and humans. Heliyon 2018;4(8):723-31. https://doi.org/10.1016/j.heliyon.2018.e00716 [DOI:10.1016/j.heliyon.2018.e00723] [PMID] [PMCID]
4. Abrham A, Zewdu S. A Review on Canine Leishmaniasis; Etiology, Clinical sign, pathogenesis, treatment and control methods. Glob Veterinaria 2016;17(4):343-52. [Google Scholar]
5. Mohebali M, Javadian E, Yaghoobi-Ershadi MR, Akhavan AA, Hajjaran H, Abaei MR. Characterization of Leishmania infection in rodents from endemic areas of the Islamic Republic of Iran. East Mediterr Health J 2004;10(4-5):591-9. [DOI:10.26719/2004.10.4-5.591] [PMID]
6. Ibarra-Meneses AV, Moreno J, Carrillo E. New Strategies and Biomarkers for the Control of Visceral Leishmaniasis. Trends in Parasitology 2020 Jan;36(1):29-38. [DOI:10.1016/j.pt.2019.10.005] [PMID]
7. Ribeiro RR, Michalick MSM, da Silva ME, Dos Santos CCP, Frézard FJG, da Silva SM. Canine Leishmaniasis: An Overview of the Current Status and Strategies for Control. Biomed Res Int. 2018;2018:3296893. [DOI:10.1155/2018/3296893] [PMID] [PMCID]
8. Macconkey S.E.,Lopez A.,Shaw D.,Calder J. leishmanial polyarthritis in a dog. Canine Vet J 2002;43:607-60. [PMCID]
9. Tomita M, Tsumoto K. Hybridoma technologies for antibody production. Immunotherapy 2011;3:371-80. [DOI:10.2217/imt.11.4] [PMID]
10. Pasqualini R, Arap W: Hybridoma-free generation ofmonoclonal antibodies. Proc Natl Acad Sci USA 2004;101 257-9. [DOI:10.1073/pnas.0305834101] [PMID] [PMCID]
11. Moritaa M, Sugiharaa H, Tokunakaa K, Tomuraa A, Saigaa K, Satoa T, Imamurab Y, Hayashic T. Preparation and partial characterization of monoclonal antibodies specific for the nascent non-triple helical form of the type IV collagen alpha 1 chain. Biochem Biophys Rep 2017;9:128-32. [DOI:10.1016/j.bbrep.2016.11.013] [PMID] [PMCID]
12. Sasidharan S, Saudagar P. Leishmaniasis: Where Are We and Where Are We Heading? Parasitol Res 2021;120(5),1541-54. [DOI:10.1007/s00436-021-07139-2] [PMID]
13. Jervis S, Chapman LAC, Dwivedi S, Karthick M, Das A, Le Rutte EA, et al. Variations in visceral leishmaniasis burden, mortality and the pathway to care within Bihar, India. Parasites Vectors 2017;10(1):601. [DOI:10.1186/s13071-017-2530-9] [PMID] [PMCID]
14. Jaffe CL, Rachamim N. Amastigote stage-specific monoclonal antibodies against Leishmania major. Infect Immun 1989;57(12):3770-7. [DOI:10.1128/iai.57.12.3770-3777.1989] [PMID] [PMCID]
15. Jaffe CL, Bennett E, Grimaldi G Jr, McMahon-Pratt D. Production and Characterization of species-specific monoclonal antibodies against Leishmania donovani for immunodiagnosis. J Immunol 1984;133(1):440-7. [DOI:10.4049/jimmunol.133.1.440] [PMID]
16. Froes AM, dos Santos CVD, Penha-Filho ML,Teixeira MCA et al. Sub-clinical infection as an effective protocol for obtaining anti-Leishmania chagasi amastigot antibodies of different animal species. Veterin Immunol Immunopathol 2004;99:135-41. [DOI:10.1016/j.vetimm.2004.01.013] [PMID]
17. Tomita M, Tsumoto K. Recent advances in antigen-based generation of monoclonal antibodies. Curr Immunol Rev 2010; 6: 56-61. [DOI:10.2174/157339510790231789]
18. Schmitz K, Geisslinger G, Tegeder I. Monoclonal antibodies in preclinical EAE models of multiple sclerosis: A systematic review. Int J Mol Sci 2017;18:1-18. [DOI:10.3390/ijms18091992] [PMID] [PMCID]
19. Kivi G, Teesalu K, Parik J, Kontkar E, Ustav M J, Noodla L, et al. HybriFree: A robust and rapid method for the development of monoclonal antibodies from different host species. BMC Biotechnol 2016;16:2. [DOI:10.1186/s12896-016-0232-6] [PMID] [PMCID]
20. Cabral-Miranda G, de Jesus JR, Oliveira PR, Detection of parasite antigens in leishmania infantum-infected spleen tissue by monoclonal antibody, piezoelectric-based immunosensors. J Parasitol 2014;100(1):73-8. [DOI:10.1645/GE-3052.1] [PMID]
21. Tigabu D., Endale B., Haben F. Monoclonal Antibody and its Diagnostic Application. Biomed J Sci & Tech Res 2020;30(4):23645-50. [DOI:10.26717/BJSTR.2020.30.004997]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Studies in Medical Sciences

Designed & Developed by : Yektaweb